Clinical Edge Journal Scan

Multiple sclerosis type and female sex predict worsening lower urinary tract symptoms


 

Key clinical point : Female sex and progressive forms of multiple sclerosis (MS) are the prognostic factors for worsening lower urinary tract symptoms in patients with MS, with neurogenic lower urinary tract dysfunction being a contributor to disease progression.

Major finding: A higher bowel/bladder functional system (FS) score, indicating worsening symptoms and functions, was significantly associated with female vs male sex ( P = .001) and progressive vs relapsing-remitting MS type ( P ≤ .001), with each point increase in the bowel/bladder FS score during follow-up visit at 1 year being associated with an increased risk of worsening disability over the subsequent year (area under curve 0.63).

Study details: This prospective study evaluated 802 patients with clinically isolated syndrome or MS.

Disclosures: This research was funded by the National Multiple Sclerosis Society, US National Institutes of Health, and Valhalla Foundation. Some authors declared receiving consulting and advisory board fees, research support, or personal compensation or serving on boards of trustees or on advisory boards for various sources.

Source: Kaplan TB et al. Challenges to longitudinal characterization of lower urinary tract dysfunction in multiple sclerosis. Mult Scler Relat Disord . 2022;62:103793 (Apr 10). Doi: 10.1016/j.msard.2022.103793

Recommended Reading

Clinical Edge Journal Scan Commentary: Multiple Sclerosis May 2022
ICYMI Multiple Sclerosis
Switching to extended-interval natalizumab dosing effective in RRMS
ICYMI Multiple Sclerosis
Progressive MS: sNfL shows promise as an effective biomarker for long-term disability progression
ICYMI Multiple Sclerosis
Anti-SARS-CoV-2 mAbs safe and effective for acute COVID-19 in immunocompromised patients with MS
ICYMI Multiple Sclerosis
RRMS: Long-term fingolimod shows positive benefit-risk profile in real-life settings
ICYMI Multiple Sclerosis
Multiple sclerosis: Greater prevalence of disease activity in women and disability accrual in men
ICYMI Multiple Sclerosis
Teriflunomide effective and well-tolerated in patients with RRMS
ICYMI Multiple Sclerosis
Long-term treatment with siponimod is effective and safe in SPMS
ICYMI Multiple Sclerosis
T-cell response after third SARS-CoV-2 vaccination in patients with MS on ocrelizumab
ICYMI Multiple Sclerosis
Multiple sclerosis: Reduced humoral response contributes to breakthrough SARS-CoV-2 infection in patients on DMTs
ICYMI Multiple Sclerosis